This first flare is rapidly followed by an accumulation in the lesional skin of T-helper (Th) 17 cells that produce proinflammatory cytokines such as IL-17 and IL-22 crosstalking with the IL-12/IL-23 axis. The clinical background of this phase is represented by papulo-pustulous lesions of psoriasis.
In the late stages of the disease, clinically characterized by plaque psoriasis, the inflammatory process is shifted to a classical Th1 cell-mediated immune response, with predominance of Th1 cell-related cytokines like tumor necrosis factor (TNF)-α and interferon (IFN)-γ [3] .
Thus, in its initial events, psoriasis seems to reproduce exactly the pathogenetic model of classic autoinflammatory diseases, such as pyogenic arthritis, acne, and pyoderma gangrenosum (PAPA) syndrome, and neutrophilic dermatoses, such as idiopathic pyoderma gangrenosum, which are due to mutations of genes regulating the innate immunity and share with psoriasis the same cascade of cytokine release and cell activation [4] [5] [6] [7] .
As well, the link between psoriasis and different autoinflammatory conditions is also given from the clinical ground, as the occurrence of a severe erythrodermic and pustular presentation of psoriasis is present in several syndromes such as Deficiency of IL-1 Receptor Antagonist (DIRA) and Deficiency of IL-36 Receptor Antagonist (DITRA) [8, 9] .
The aforementioned physiopathological model may support the view on psoriasis as a paradigm of skin disease with systemic involvement and hallmarked by an important autoinflammatory component.
A comprehensive knowledge of the complex interplay among the genetic/epigenetic factors and immunological mechanisms of autoinflammation should contribute to the development of novel targeted therapeutic strategies.
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